Recommendation of the President – Luxturna (voretigene neparvovec)

On 19 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 127/2024 on the appraisal Luxturna (voretigene neparvovec) under the drug program: “Treatment of patients with Leber congenital blindness (LCA) with biallelic mutation of the RPE65 gene (ICD-10: H35.5)”

Publication in Public Information Bulletin (BIP) >>